Barw Barw Medical Journal 2960-1959 2024 12 02 Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials 10.58742/bmj.v2i4.146 eng Fahmi H. Kakamad College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Iraq. fahmi.hussein@univsul.edu.iq Sami S. Omar Rizgary Oncology Center, Erbil, Iraq. sami.omar@gmail.com Farman J. Ahmed Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq. farman.ahmed@gmail.com Dana H. Mohammed Saeed Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq. dana.saeed@gamil.com Rebaz M. Ali Hiwa Cancer Hospital, Sulaimani Directorate of Health, Sulaymaniyah, Iraq. rebaz.ali12@gmail.com Marwan N. Hassan Kscien Organization for Scientific Research (Middle East Office), Hamdi Street, Azadi Mall, Sulaymaniyah, Iraq. marwan.nasih12@gmail.com Karokh F. Hamahussein Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq. karokh12@gmail.com Nsren S. Sabr Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq. nsren.sabr@gmail.com Hawkar A. Nasralla Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq. hawkar.arf96@gmail.com Mohammed Q. Mustafa Department of Medical Analysis, Tishk International University, Erbil, Iraq. mohammed111@gmail.com Diyar A. Omar Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Iraq. diyar.omar@gmail.com Soran H. Tahir Scientific Affairs Department, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq. soran.tahir@univsul.edu.iq Rezheen J. Rashid Hiwa Cancer Hospital, Sulaimani Directorate of Health, Sulaymaniyah, Iraq. rezheen.rashid@gmail.com Tara N. Mohammed Xzmat polyclinic, Rizgari, Kalar, Sulaymaniyah, Iraq. tara.mohammed@gmail.com Shvan H. Mohammed Xzmat polyclinic, Rizgari, Kalar, Sulaymaniyah, Iraq. shvanh80@gmail.com 2024 10 25 Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban were introduced, consequently becoming the controversial oral anticoagulants for VTE therapy. This study is a meta-analysis of randomized clinical trials (RCTs) evaluating the use of edoxaban for treating VTE in cancer patients over different treatment durations. Methods Using Google Scholar, a systematic search for RCTs on edoxaban for cancer-associated VTE was performed. The data extracted covered patient numbers, age, gender, BMI, cancer type, edoxaban dosage, treatment duration, comorbidities, major bleeding, recurrent VTE incidence, and deaths. Statistical significance was set at 0.05. Results Out of 52 studies, nine with 3,190 cases met the inclusion criteria. The mean age was 66.68 years, with 1,604 females (50.28%). Major bleeding occurred in 192 patients (7.66%) in the 6- or 12-month group and 57 (8.35%) in the 3-month group (p=0.573). Recurrent VTE was observed in 145 patients (5.78%) in the 6- or 12-month group and 95 (13.91%) in the 3-month group (p<0.001). Deaths from any cause totaled 548 (21.86%) in the 6- or 12-month group and 165 (24.16%) in the 3-month group (p=0.110). Conclusion Cancer patients receiving edoxaban for six or 12 months experience a lower recurrence rate of VTE compared to those on a 3-month treatment. The incidence of major bleeding appears to be similar between the two treatment durations.